Oor dokter
Dr Benjamin Levy is 'n torakale mediese onkoloog wat ook dien as die kliniese direkteur van mediese onkologie vir die Johns Hopkins Sidney Kimmel Kanker Sentrum by Sibley Memorial Hospitaal en as 'n medeprofessor in onkologie by Johns Hopkins Universiteit Skool vir Geneeskunde. Hy werk uit die Sibley Memorial Hospitaal se Johns Hopkins Sidney Kimmel Cancer Centre.
Dr. Levy is a clinician scientist who is interested in novel immunotherapeutic treatments for patients with advanced Long kanker, as well as biomarkers that help identify those patients who are more likely to respond to such medicines. He specialises in thoracic malignancies such as non-small cell lung cancer, small cell lung cancer, thymic malignancies, and kop en nek kanker.
Dr. Levy graduated from the Medical College of Georgia. He completed an internal medicine residency at Georgetown University Hospital, followed by a hematology/oncology fellowship at New York Presbyterian/Weill Cornell Medical Centre, where he received the Department of Medicine Research Fellow of the Year Award and the 2009 American Society of Clinical Oncology Young Investigator Award for his prostaatkanker clinical research. Dr. Levy previously worked as an assistant professor at the Icahn School of Medicine, as the medical director of thoracic oncology for Mount Sinai Health Systems, and as the associate director of Mount Sinai Hospital’s Cancer Kliniese proewe Kantoor.
Dr Levy het op talle American Society of Clinical Oncology (ASCO) komitees gedien en is tans 'n mederedakteur vir die ASCO Universiteitskomitee. Hy het vir twee jaar op die redaksie van die Journal of Clinical Oncology gedien en is tans 'n ad hoc-beoordelaar vir bykomende publikasies soos Clinical Lung Cancer, The Oncologist en Onco target. Dr. Levy is onlangs gekies as een van net 15 onkoloë in die land om deel te neem aan die gesogte ASCO-leierskapontwikkelingsprogram, wat daarop gemik is om toekomstige ASCO-leiers te ontdek en op te lei. Dr Levy dien ook op die ALLIANCE Respiratoriese Komitee, die IASLC Staging Committee, en die IASLC Loopbaanontwikkeling & Fellowship Committee bykomend tot sy ASCO-aktiwiteite.
Hospitaal
Spesialisasie
Prosedures uitgevoer
- Long kanker
- immunoterapie
Navorsing en publikasies
Becker DJ, Wisnivesky JP, Grossbard ML, Chachoua A, Camidge DR, Heffing BP. "Oorlewing van Asiatiese vroue met gevorderde longkanker in die era van tyrosienkinase-inhibeerderterapie." Kliniese longkanker. 2017 Jan;18(1):e35-e40. doi: 10.1016/j.cllc.2016.08.008.
Heffing BP, Rao P, Becker DJ, Becker K. "Aanval 'n bewegende teiken: Verstaan weerstand en bestuur vordering in EGFR-positiewe longkankerpasiënte wat met tyrosienkinase-inhibeerders behandel word." Onkologie (Williston Park). 2016 Jul;30(7):601-12. Resensie.
Heffing BP, Chioda MD, Herndon D, Longshore JW, Mohamed M, Ou SH, Reynolds C, Singh J, Wistuba II, Bunn PA Jr, Hirsch FR. "Molekulêre toetsing vir die behandeling van metastatiese nie-kleinsel longkanker: hoe om bewysgebaseerde aanbevelings te implementeer." onkoloog. 2015 Okt;20(10):1175-81. doi: 10.1634/theoncologist.2015-0114.
Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Heffing BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS . "Aktiwiteit en veiligheid van nivolumab, 'n anti-PD-1 immuun kontrolepunt inhibeerder, vir pasiënte met gevorderde, vuurvaste plaveisel nie-kleinselle longkanker (CheckMate 063): 'n fase 2, enkelarm proef." Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9.
Heffing BP, Becker DJ. "Die tyd vir lae-dosis rekenaartomografie sifting is nou: 'n mediese onkoloog perspektief." Onkologie (Williston Park). 2014 Nov;28(11):964-6. Geen abstrak beskikbaar nie.
